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Summary.-One hundred and sixty women admitted for breast tumour biopsy to
the King's College Hospital group have been followed sequentially for 2 years.
Sixty-nine women had early operable breast cancer and 91 had benign breast disease.
All these women had serum immunoglobulin IgG, IgA, IgM and IgE levels measured
preoperatively and postoperatively at 3 months, 1 year and 2 years. No differences
were found in any of the serum immunoglobulin levels between the two groups at
any time. There was, however, a positive correlation between the extent of metastatic
breast cancer and the serum level of various immunoglobulins, particularly IgA.
There was no evidence that routine postoperative radiotherapy influenced the levels
of serum immunoglobulins. The findings suggest a secondary defence reaction
against increasing tumour load, and do not support the theory of an early immune
defect in immunoglobulin metabolism which could play a part in the pathogenesis
of breast cancer. Although there is no diagnostic value in measuring the levels of
serum immunoglobulins in patients with breast tumours, there may be some value
in following the levels in cancer patients, as a guide to subclinical spread of the
disease.
THERE is evidence that the measure-
ment of serum immunoglobulin levels
may be useful in the management of
cancer patients in three separate ways:
as a diagnostic indicator, as an indicator
of tumour spread or as an indicator
of immunosuppression in the pathogenesis
of cancer.
In a large survey of patients suffering
from various non-haematopoietic cancers,
serum levels of the immunoglobulins
IgG, IgA and IgM were found to be
altered (Hughes, 1971). Patients with
carcinomas of the skin and lung had
elevated serum levels of IgG and IgA,
whereas patients with tumours of the
gastrointestinal tract and uterus had
increased serum levels of IgA only.
Serum levels of IgM were unaffected,
except in male patients with sarcomas
and female patients with melanoma.
Although the above study did not find
differences in the levels of serum immuno-
globulins in patients with breast cancer,
two other studies have reported higher
serum levels of IgA in breast cancer
patients than in control patients with
benign breast disease (Rowinska-Zakrew-
ska, Lazar and Burtin, 1970; Roberts,
Bathgate and Stevenson, 1975).
It has also been suggested that patients
with breast cancer who have increased
levels of serum IgA before mastectomy
have an improved prognosis (Meyer,
Mackler and Beck, 1973).
Patients with breast cancer have been
reported to suffer significantly less from
allergic diseases than do controls without
cancer (Mackay, 1966). The relationship
of this observation to the pathogenesis
of cancer is unknown, although there is
some evidence that atopic subjects are
"high responders" (i.e. more readily make
antibodies to foreign substances than doPROGNOSIS OF BREAST CANCER
non-atopic subjects (Platts-Mills et al.,
1976)).
Cancer patients were found to have
slightly lower than normal IgE levels,
according to single radial immunodiffusion
(Augustin and Chandradasa, 1971) and
so they might possibly be regarded as
"low responders". However, normal IgE
levels are much lower (Nye et al., 1975)
than was originally believed, and are
below the limits of immunodiffusion
procedures.
The value of previous studies has been
limited by a number of factors. Firstly,
no study has reported changes in serum
immunoglobulin levels followed serially
in the same subjects over an extended
period of time. Secondly, only rarely
has the extent of the disease been con-
sidered or the effects of potentially
immunosuppressive therapy (e.g. radio-
therapy or cytotoxic drugs). Finally,
although the distributions of each of the
serum immunoglobulin levels is log-
normal, statistical comparisons have been
made on data without logarithmic trans-
formation.
This study was undertaken to determine
(a) whether the serum levels of immuno-
globulins IgG, IgA, IgM and IgE changed
in early breast cancer compared to non-
malignant breast disease: (b) whether
changes in serum levels of immuno-
globulins could be correlated with the
spread of the tumour. The results of the
first 2 years are reported here.
PATIENTS AND METHODS
One hundred and sixty women admitted
to King's College Hospital for breast tumour
biopsy have been studied. Sixty-nine of
these women were found to have breast
cancer and 91 non-malignant breast disease.
All the women were less than 70 years
of age and had breast lumps less than
5 cm in diameter, with or without palpable
ipsilateral axillary glands. Those with breast
cancer therefore had tumours which fell into
Clinical Stage I or II of the Manchester
classification (Wise, Mason and Ackerman,
1971) and had no evidence of clinically
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occult mietastases as shown by routine
chest X-ray, liver function tests and serum
chemistry or bone scanning.
The 2 groups of women had venous
blood sampled the day before operation,
and subsequently they have had further
samples taken 3 months postoperatively
and then annually for between 2 and 3
years.
A careful clinical record has been kept
of each cancer patient. A system for quanti-
fying the approximate tumour mass in each
cancer patient was devised to produce the
clinical score, so that correlations between
the immunoglobulin levels and the extent
of the cancer could be performed. This
scoring system was based upon the diameter
of the breast tumour measured postopera-
tively, and additional points were given
for evidence of histological spread of the
tumour to involve skin, pectoral muscles
or lymph nodes. Postoperatively the score
was increased for local recurrence of the
tumour in the scar or lymph nodes and for
the development of each metastatic lesion
confirmed by biopsy. Equal weighting was
given to proven metastases, irrespective
of site, and the score modified if a lesion
increased or decreased in size. A reduced
weighting was given to symptoms or in-
vestigations which suggested metastatic
spread, before a lesion was confirmed (e.g.,
persistent backache). Details of the scoring
system are given in an Appendix.
Serum was separated from the blood
samples, divided into aliquots, coded and
stored at - 20°C. Samples were randomized
and analysed in batches of 50. Estimations
of immunoglobulins IgG, IgA and IgM were
made, using single radial immunodiffusion
on commercial Tripartigen plates (Hoechst
Ltd). Total serum IgE levels were measured
using radioimmunoassay as previously de-
scribed in detail (Merrett and Pantin, 1975).
Serum IgE levels were measured in only 100
patients preoperatively and 110 patients at
follow-up.
RESULTS
A. Comparison between the two diagnostic
populations
The serum levels of immunoglobulins
G, A, M and E in breast cancer patients
were not significantly different from the
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TABLE I. Comparison ofSerum Imnmunoglobulin Levels between Patients with
Breast Cancer and those with Benign Breast Disease
IgG
Pre-operative
3 months
1 year
2 years
IgA
Pre-operative
3 months
1 year
2 years
TgM
Pre-operative
3 months
1 year
2 years
IgE
Pre-operative
3 months
1 year
2 years
Cancer
A A
AIean ,S.dl.
2 97 (933 4)
3-07 (1174-9)
3 07 (1174 9)
2 99 (977 - 3)
2 - 32 (208 5)
2-30 (198-4)
2 - 29 (194 -4)
2-21 (162-2)
1 95 (88 2)
1-96 (90 9)
2-02 (103-6)
2-04 (109-7)
1-39 (24 5)
1-41 (25 8)
1-47 (29 4)
1-40 (25-1)
0-21
0-18
0-13
0-15
Benign
Mlean s.cd.
2-96 (916-1)
3-10 (1248-8)
3-10 (1248-8)
3-02 (1047-2)
0 23 2 27 (184 9)
026 2-33(212-7)
0 26 2 -29 (194 -4)
0-23 2-21 (162-2)
0-22 2-01 (101-5)
0 29 2 00 (99 49)
0 29 2 08 (121 5)
024 2-10(125-9)
0 63 1-60 (40 0)
0 58 1-44 (27 4)
0-60 1-51 (32 5)
0 87 1-32 (20 9)
Mean values shown as logarithms to base 10 (antilog
A and M and u/mI for JgE shown in brackets). All
significant.
levels in patients with benign breast
disease, either pre-operatively or at any
of the follow-up times (Table I).
B. Correlation of serum immunoglobulin
levels with patients' age
Although the mean ages of the 2
diagnostic groups differed significantly
(benign group 45 years; cancer group
52 years), correlation analysis between
the serum immunoglobulin level and age
of the patients failed to reveal any
statistically significant relationship in
either group at any time.
C. Correlation of serum immunoglobulin
levels with metastatic spread
At 24 months after mastectomy, 13
patients from the original 69 had de-
veloped definite clinical evidence of meta-
static disease, and 6 patients had died
of breast cancer. As expected, comparison
of these patients as a group with the
remaining cancer patients did not reveal
statistically significant differences in their
to base 10 of mean expressed in mg/100 ml for IgG,
compaiisons between Cancer ancd Benign are non-
serum immunoglobulin levels at any of
the follow-up times, due to their small
number. However, correlation analysis
between the serum immunoglobulin levels
and the clinical score of each cancer
patient did show a small but significant
positive correlation with IgA at one
year (r- 029, P < 0.05) and at 2
years (r = 026). There was also a sig-
nificant negative correlation with IgM
at 3 months (r 026, P < 0.05) (Table
II).
TABLE II. Correlation (Pearson Coeffi-
cient, r) between Serum Immunoglobulins
and Clinical Scores in Breast Cancer
Patients
Post- Post- Post-
Pre- operative operative operative
operative 3 month 1 year 2 year
correlation correlation correlation correlation
3G 0 05 0.10
-A 0-12 -0-20
AI 0-09 -0-26*
rE -0 21 0-02
*J' < 0 05.
0-25
0-29*
-0 05
0-11
0 20
0 26
0-10
0-13
0-20
0-15
0-16
0-12
0 25
0-32
0-27
0-23
0 23
0 30
0-24
0 -21
0 68
0-65
0-66
0-78
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Number
of
Patients
20
15-
10-
Si
10 15
Preoperative Clinical Score
Number
of
Patients
Number
of
Patients
Number
of
Patients
601
40
20-
0 5 10 15
3 Months Postoperative Score
30-
10
0 5 ~~ ~ ~~10 15
1 Year Postoperative Score
2 Year Postoperative Score
Fia. Distribution of clinical scores among
the bireast cancer patients at different
times.
The distribution of clinical scores of
the cancer patients at the various follow-
up times is shown in the figure. Since so
few patients have developed high scores
even after 2 years, individuals with
proven metastases were examined separ-
ately and the following general conclusions
were drawn.
1. There was no uniform pattern of
serum immunoglobulin response in pa-
tients with metastatic breast cancer.
2. Considerable rises in one or more
of the serum immunoglobulin levels (from
75 to 300%0), particularly IgG and IgA,
but occasionally IgM and IgE, were seen
in the majority of patients (9 out of 13)
before the clinical appearance of their
metastases.
3. Preoperative elevation of serum IgG
level (> 2 g/100 ml) was usually asso-
ciated with early metastatic disease (4/5
patients).
4. Preoperative elevation of serum IgA
level (> 450 mg/100 ml) was rarely asso-
ciated with metastatic disease in the
first 2 years (1/7) particularly if the
serum level fell progressively.
D. The effect8 of therapy on serum im-
munoglobulin levels
The patients with breast cancer were
allocated at random to one of 2 treat-
ment groups in the King's/Cambridge
breast trial (Baum, Edwards and Magarey,
1972), and 25 patients received routine
postoperative radiotherapy to the ipsi-
lateral axillary nodes between the time
of mastectomy and the 3-month follow-up
sample. These patients as a group had
significantly lower mean serum IgM and
IgE levels preoperatively, and also signi-
ficantly lower mean serum lgM levels
at 3 and 12 months postoperatively, than
in breast cancer patients who did not
receive radiotherapy (Table III). There
was no evidence that the group not
receiving radiotherapy were clinically
more advanced than those who did not.
(No IgE levels were measured at 2 years
postoperatively.)
Individual patients who subsequently
developed metastatic breast cancer re-
ceived various additional forms oftherapy,
including radiotherapy, chemotherapy and
hormone-replacement therapy. Although
reductions in some of the immuno-
globulin levels were seen, especially in
serum IgG, it was not possible to separate
the effects of the therapy from those of
the disease process.
DISCUSSION
This study has not demonstrated any
alteration in the levels of serum immuno-
globulins IgG, IgA, IgM or IgE in patients
with breast cancer relative to patients
with benign breast lumps, when followed
prospectively for 2 years. We have not,
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TABLE III. Effect of Radiotherapy on Serum Immunoglobulin Levels
in Breast Cancer Patients
Radiotherapy Serum Number of
grouip immunoglobtulin cases
Pre-operative
Without IgG 42
With 25
Withouit IgA 42
With 25
Withotut TgM 42
With 25
Without IgE 28
With 11
Without
With
Without
With
Without
With
Without
With
Without
With
Without
With
Without
With
Without
With
Withotut,
With
Without
With
Without
With
At 3 months
TgG
IgA
TgM
IgE
At 1 year
IgG
IgA
TgM
JgE
At 2 years
IgG
JgA
TgM
40
20
40
20
40
20
32
12
28
19
28
19
28
18
28
15
26
16
26
16
26
16
Mean values shown as logarithms to base 10 (antilog
JgG, A and M an(1 u/ml for IgE shown in parentheses).
NS = Not significant.
therefore, confirmed the finding ofelevated
serum IgA levels in breast cancer patients
reported by Rowinska-Zakrewska et al.
(1970) and by Roberts et al. (1975).
However, the patients in our study were
especially selected to be at the earliest
clinical stage of their disease and, since
serum IgA levels may rise with advancing
disease, this difference in the selection
of patients, plus the statistical analysis
on logarithmically transformed data, mav
account for our differing results.
The model IgE value in a non-atopic
population was found to be 21 u/ml (Nye
et al., 1975) and 38 u/ml in a population
of mean to base 10 expressed in mg/100 ml for
that excluded asthma and chronic bronch-
itis sufferers (Burr et al., 1975).
The modal value obtained in this
study are not significantly different, al-
though the number of breast cancer
patients with a history of atopic allergies
(6/69) was significantly lower than the
control group (20/91) (P < 0.05). There
is therefore no diagnostic value in measur-
ing the levels of serum immunoglobulins
in patients with breast tumours.
However, the measurement of serum
immunoglobulin levels in breast cancer
patients may be of some value as an
indicator of tumour spread. There is a
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s.cl. I, MeanI
3-01 (1012 4)
2 93 (845 5)
2 33 (214 8)
2 29 (194.4)
1 98 (96 5)
1 88 (75 2)
1 56 (36 3)
0 94 (8 8)
3 05 (1130 1)
3-10 (1248-8)
2 28 (188 7)
2 33 (212 7)
2 01 (101-5)
1 85 (71 5)
1 48 (30 X3)
1 21 (16 1)
3 08 (1211 8)
3 08 (1199 9)
2 29 (194 *4)
2 28 (192.4)
2 08 (121 5)
1 90 (79 8)
1 55 (35 9)
1 30 (19 9)
2 99 (982 4)
2 98 (963 0)
2 16 (145 5)
2 28 (188 7)
2 05 (111 1)
2 02 (103 6)
0-21
0-21
0 24
0 22
0 24
0 16
0.55
0 60
0-15
0 22
0 27
0 25
0-31
0 22
0*51
0 71
0 13
0-12
0 28
0 25
0 29
0 23
0 60
0 58
0 14
0-16
0-21
0 24
0 25
0-21
NS
NS
0 027
0 004
NS
NS
0 054
NS
S7S
NS
00-031
NS
NS
NS
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positive correlation between serum IgA
level and the advancement of metastatic
breast cancer, as quantified by the
clinical score. Analysis of individuals who
have subsequently developed metastases
confirms that large rises in serum immuno-
globulins, particularly IgG and IgA, may
antedate the detection of metastases.
At present it is impossible to detect,
let alone quantify, subelinical spread of
breast cancer, and the present scoring
must clearly underestimate the tumour
mass of many patients, particularly in
the first few postoperative months. Subse-
quently, the effects of the advancing
disease and coincident therapies upon
the serum immunoglobtilin levels may
be impossible to differentiate.
The association of advancing meta-
static breast cancer with rises in serum
immunoglobulin levels ofall major classes,
but particularly IgA and IgG, suggests
a defence reaction against increasing
tumour load or the secretion of immuno-
globulins by the tumour.
The first hypothesis is supported by
our previous finding of a highly significant
correlation between preoperative serum
IgA and IgM levels and the degree of
mononuclear infiltrate of the primary
breast tumour (r 0 40 and 0 30 re-
spectively) (Tee and Pettingale, unpub-
lished).
In addition, we have found diverse
changes in other serum proteins in our
patients with breast cancer (Pettingale
and Tee, 1977) which are more likely to
result from an indirect effect of the
tumour.
The authors would like to thank
Patricia White and Kevin Ryan for
their help with the statistical analysis;
they are grateful to the patients for
their willing cooperation and to their
colleagues on the Faith Courtauld Unit
for Human Studies in Cancer at King's
College Hospital Medical School for their
help.
APPENDIX
Clinical Scoring System
General Instructions
(1) The score is a systeni for quantifying the approximnate total tumour mass in a patient
with breast cancer at different times.
(2) The score should be calhulated prospectively and corrected retrospectively when
confirmatory investigations have established or refuted progression of the disease. This
particularly applies to Section II (ii, iii and iv). Only when metastatic spread has been con-
firmed and there is measurable evidence that spread had occurred before this confirmation
should the additional scores under these sections be allocated.
(3) If any clinical, biochemical or other feature could be explained by any non-tumour
pathology, no score should be allocated.
(4) Change in size ofexisting lesions should only be based on objective measurements.
1. Pre-operative
(a) Local
Score
Initial tumour diameter (operative specimen) in cm +1 per cm
Histological evidence of superficial or deep involvement +1
(either/both)
Histological node involvement -t1 for eacl
al region
(b) Add score of any systemic involvement (as below)
(c) After operation subtract, the local score
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II. Post-operative
(a) Local. Persistence/recurrence in node, scar etc.
(b) Systemic
(i) Confirmed (e.g. biopsy/X-ray/cytology)
Bone
Lung
Liver
Other
(e.g. marrow)
(ii) Suspected symptoms/clinical examination non-specific
investigations (e.g. radioisotope scanning)
Bone
Lung
Liver
Other
(iii) Unexplained biochemical abnormality alone (elevated
enzymes)
(iv) Additional general symptoms (e.g. weight loss, fever,
malaise, anaemia, etc.)
III. At each continuing assessment
(a) New system confirmed
(b) New system suspected
(c) Increase in size of existing lesion (for each)
(d) Decrease in size of existing lesion
(e) No change in size
Example
Pre-operative.-Woman with 5 cm tumour with superficial
involvement + tumour in nodes. Raised
serum LDH.
Score: 5 + 1 + 1 + 1 = 8
Post-operative score.-+ 1 to carry forward
At 3-months follow-up: LDH higher, but well +1
At 6-months follow-up: backache, X-ray, -ve +3
At 9-months follow-up: X-rays now show lytic lesions, +2
alkaline phosphatase now
raised, and LDH raised more +1
At 10-months follow-up: radiotherapy
At 12-months follow-up: backache better
lesions smaller -1
serum enzyme levels down -1
At 15-months follow-up: dyspnoea
CXR shows pleural effusion
oophorectomy +5
At 16-months follow-up: no change 0
At 18-months follow-up: cytotoxics into pleural effusion -1
responds
At 20-months follow-up: very ill-fever, weight loss, etc. +1
At 21 months: dies.
Total +2
Total +5
(to make confirmed score)
Total +8
Total +6
Total +11
Total +11
Total +10
Total +11
+3
+5
+5
+5
+5
+3
+3
+3
+3
+1
+1
+5
+3
+1
-1
0
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